Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Choosing between stem cell therapy and drugs in myelofibrosis.

Kröger N, Mesa RA.

Leukemia. 2008 Mar;22(3):474-86. doi: 10.1038/sj.leu.2405080. Epub 2008 Jan 10. Review.

PMID:
18185525
2.

Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.

Hogan WJ, Litzow MR, Tefferi A.

Curr Hematol Malig Rep. 2007 Feb;2(1):34-42. doi: 10.1007/s11899-007-0005-3. Review.

PMID:
20425386
3.
4.

No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.

Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1350-1. No abstract available.

5.

Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.

Mesa RA, Tefferi A.

Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. doi: 10.1517/14728210903066809. Review.

PMID:
19552608
6.

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.

Slot S, Smits K, van de Donk NW, Witte BI, Raymakers R, Janssen JJ, Broers AE, Te Boekhorst PA, Zweegman S.

Bone Marrow Transplant. 2015 Nov;50(11):1424-31. doi: 10.1038/bmt.2015.172. Epub 2015 Aug 3.

PMID:
26237165
7.

Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.

Alchalby H, Kröger N.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S36-41. doi: 10.1016/j.clml.2014.06.012. Review.

PMID:
25486953
9.

MPN blast phase: clinical challenge and assessing response.

Mesa RA, Tibes R.

Leuk Res. 2012 Dec;36(12):1496-7. doi: 10.1016/j.leukres.2012.08.026. Epub 2012 Sep 19. No abstract available.

PMID:
22999527
10.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Barosi G, Bacigalupo A.

Curr Opin Hematol. 2006 Mar;13(2):74-8. Review.

PMID:
16456372
11.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM.

Blood. 2009 Dec 17;114(26):5264-70. doi: 10.1182/blood-2009-07-234880. Epub 2009 Oct 7.

12.

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.

Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI; Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT).

Biol Blood Marrow Transplant. 2010 Oct;16(10):1419-27. doi: 10.1016/j.bbmt.2010.04.006. Epub 2010 Apr 24.

13.

Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need.

Shimoni A, Nagler A.

Best Pract Res Clin Haematol. 2011 Sep;24(3):369-79. doi: 10.1016/j.beha.2011.05.002. Epub 2011 Jun 24. Review.

PMID:
21925090
14.

Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis.

Torka P, Hahn T, Bertolo J, Liu H, Ross M, Paplham P, Jankowski A, Deeb G, Chen G, McCarthy P.

Bone Marrow Transplant. 2015 Nov;50(11):1480-2. doi: 10.1038/bmt.2015.169. Epub 2015 Jul 27. No abstract available.

PMID:
26214139
15.
16.

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.

Tefferi A.

Am J Hematol. 2013 Feb;88(2):141-50. doi: 10.1002/ajh.23384. Review. Erratum in: Am J Hematol. 2013 May;88(5):437-45.

17.

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

Tefferi A, Vainchenker W.

J Clin Oncol. 2011 Feb 10;29(5):573-82. doi: 10.1200/JCO.2010.29.8711. Epub 2011 Jan 10. Review.

PMID:
21220604
18.

Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.

TAHARA K, YOKOHAMA A, HANDA H, SAITOH T, UCHIUMI H, SEKIGAMI T, TOYAMA K, MAWATARI M, OSAKI Y, MATSUSHIMA T, KARASAWA M, MURAKAMI H, TSUKAMOTO N, NOJIMA Y.

Rinsho Ketsueki. 2009 Nov;50(11):1630-4.

PMID:
20009439
19.

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.

Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM; MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.

Exp Hematol. 2007 Nov;35(11):1719-22.

PMID:
17976523
20.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713

Supplemental Content

Support Center